Johnson & Johnson Clinical Trials Show Progress Across Key Therapies
Johnson & Johnson shares key clinical trial results for Tremfya in psoriatic arthritis and five-year Carvykti data in multiple myeloma.
Stocks · News reference
Johnson & Johnson Announces That TREMFYA Met Primary And Major Secondary Endpoints Demonstrating Both Improvement In Axial Symptoms And Reduction In Inflammation By MRI Assessment In The Phase 4 STAR Study Evaluating Biologic-Naïve Adults With Active Psoriatic Arthritis And Axial Involvement
STAR is the first and only dedicated randomized, double-blind, placebo-controlled study of its kind designed to prospectively evaluate an IL-23 inhibitor specifically in patients with axial involvement confirmed by
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Johnson & Johnson Says 50% Of Patients Progression-Free At Five Years After Single Carvykti Infusion In Phase 2 Multiple Myeloma Trial
8 Of 11 Sectors Fall In Thursday Trading As Leaders Split
Three sectors are higher and eight are lower in Thursday’s regular session, with growth, cyclical and defensive sectors each represented among the top three. The leaders are separated rather than